Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	35.15B
Revenue (ttm)	12.93B
Net Income (ttm)	2.38B
Shares Out	n/a
EPS (ttm)	2.62
PE Ratio	14.78
Forward PE	14.65
Dividend	1.20 (3.52%)
Ex-Dividend Date	Jun 13, 2025

Volume	1,191,919
Average Volume	1,248,020
Open	34.30
Previous Close	34.02
Day's Range	34.16 - 34.78
52-Week Range	24.85 - 41.85
Beta	0.27
RSI	42.20
Earnings Date	Oct 24, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People’s Republic of China. The company offers Ilaprazole enteric-coated tablets and ilaprazole sodium for injection a series of bismuth potassium citrate products for gastrointestinal field; leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for assisted reproduction field; fluvoxamine maleate and perospirone hydrochloride tablets for psychiatric...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY